Press Releases

 
Press Releases
  Date Title and Summary View
Jul 21, 2016
- Acquisition Strengthens Galenica's Business Unit, Vifor Pharma - Galenica will commence a tender offer to acquire all issued and outstand...
Jul 18, 2016
REDWOOD CITY, Calif., July 18, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on July 5, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 5,700 shares of the company's common stock with a per share exercise pric...
Jul 6, 2016
REDWOOD CITY, Calif., July 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the Cantor Fitzgerald 2nd Annual Healthcare Conference on July 12, 2016 at 2:30 p.m. ET. To access the live webcasts and subsequent archived recordings of these present...
Jun 27, 2016
REDWOOD CITY, Calif., June 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that results of a pre-specified exploratory analysis of the Phase 3 OPAL-HK trial of Veltassa® (patiromer) for oral suspension were published online by Kidney International, the journal of the International Societ...
Jun 17, 2016
REDWOOD CITY, Calif., June 17, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 15, 2016, the compensation committee of the company's board of directors granted 8 new employees options to purchase an aggregate of 27,750 shares of the company's common stock with a per share exercise pr...
Jun 6, 2016
REDWOOD CITY, Calif., June 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on June 1, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 6,250 shares of the company's common stock with a per share exercise pric...
May 25, 2016
REDWOOD CITY, Calif., May 25, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) requesting label changes for Veltassa® (patiromer) for oral suspension based on results of 12...
May 22, 2016
REDWOOD CITY, Calif., May 22, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that data from new analyses of studies with Veltassa® (patiromer) for oral suspension were presented at the 53rd Congress of the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) ...
May 18, 2016
REDWOOD CITY, Calif., May 18, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on May 16, 2016, the compensation committee of the company's board of directors granted 4 new employees options to purchase an aggregate of 10,400 shares of the company's common stock with a per share exercise pric...
May 5, 2016
REDWOOD CITY, Calif., May 05, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on May 2, 2016, the compensation committee of the company's board of directors granted 2 new employees options to purchase an aggregate of 5,700 shares of the company's common stock with a per share exercise price ...
Page:
1
... NextLast
= add release to Briefcase